Home › Funds › Fairmount Funds Management LLC › VRDN

Fairmount Funds Management LLC position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Fairmount Funds Management LLC reported holding 5,090,928 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$93.5M, representing 6.18% of its reported portfolio and ranking #7 among its reported holdings. Fairmount Funds Management LLC has disclosed VRDN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)5.09M sh
Reported value held$93.52M
Portfolio Weight6.18%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Fairmount Funds Management LLC's VRDN position evolved

Fairmount Funds Management LLC first disclosed a stake in VRDN in Q3 2023 at 1,369,623 shares (US$21.0M). The position peaked in Q4 2025 at 3,914,458 shares, worth US$121.8M. Across 12 filings, Fairmount Funds Management LLC increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 5,090,928 shares valued at US$93.5M — an increase of 1,176,470 shares quarter over quarter.. Notable position changes include a 35% increase in Q1 2024 (shares fell 26% over the following quarter), a 87% increase in Q3 2024 (shares fell 16% over the following quarter), a 30% increase in Q2 2026 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.37M $21.01M New
Q4 2023 1.37M $29.83M Hold
Q1 2024 1.85M $32.32M Add
Q2 2024 1.85M $24.01M Hold
Q3 2024 3.45M $78.39M Add
Q4 2024 3.45M $66.06M Hold
Q1 2025 3.45M $46.45M Hold
Q2 2025 3.46M $48.37M Hold
Q3 2025 3.46M $74.66M Hold
Q4 2025 3.91M $121.82M Add
Q1 2026 3.91M $76.57M Hold
Q2 2026 5.09M $93.52M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Fairmount Funds Management LLC held VRDN?

Fairmount Funds Management LLC has disclosed VRDN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Fairmount Funds Management LLC's current position in VRDN?

As of Q2 2026, Fairmount Funds Management LLC holds 5.09M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $93.52M, representing 6.18% of its reported portfolio and ranking #7.

Has Fairmount Funds Management LLC been buying or selling VRDN?

In the latest 13F filing (Q2 2026), Fairmount Funds Management LLC increased its position in VRDN. The position peaked in Q4 2025 at 3.91M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.